ArticleFrontiers in medicine2026
Validation of the Gazelle point-of-care device for hemoglobin variant analysis in a predominantly pediatric population: performance comparison with conventional electrophoresis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is a group of genetic hemoglobinopathies that lead to significant morbidity and mortality including vaso-occlusive crises, hemolysis, and progressive organ damage. Early detection is critical to initiate disease-modifying therapy and prevent complications; however, conventional hemoglobin electrophoresis is often unavailable in low-resource settings where SCD is most prevalent. Point-of-care (POC) devices offer a potential solution by enabling rapid, low-cost screening. The Gazelle POC instrument, which separates hemoglobin variants (A, F, S, and A2/CE) on a cellulose acetate membrane, has been evaluated in limited populations, but its performance relative to conventional electrophoresis methods in pediatric samples remains underexplored. This study validated the analytical and clinical performance of Gazelle using predominantly pediatric whole blood. Precision, linearity, and method comparison studies were conducted with quality control materials and 46 clinical samples analyzed on both Gazelle and the Sebia Capillarys system. Results showed variable precision across hemoglobin variants, strong linearity for Hb A (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.